期刊文献+

帕金森病患者脑脊液中miR-133b的表达及其临床意义 被引量:2

Expression of miR-133b and its clinical significance in cerebrospinal fluid of patients with Parkinson's disease
下载PDF
导出
摘要 目的检测miR-133b在帕金森病(PD)患者脑脊液中的表达情况,为帕金森病的早期诊断提供参考依据。方法采用实时荧光定量RT-PCR检测46例PD患者、25例头痛患者和22例健康人脑脊液中miR-133b表达水平。分析脑脊液中miR-133b表达水平与PD相关临床指标的关系。结果 PD组患者脑脊液中miR-133b相对表达水平明显高于头痛组和健康对照组(P均<0.05),且PD患者脑脊液中miR-133b表达与帕金森综合评分量表(UPDRS)分级呈正相关(r=0.74,P<0.05)。ROC曲线确诊PD患者的脑脊液miR-133b临界值为0.672,其诊断敏感度为87.7%,特异度为79.3%。结论脑脊液miR-133b的检测不仅有助于PD的诊断,也可能作为判断PD病情的指标之一。 Objective It is to detect the expression of miR -133 b in cerebrospinal fluid of patients with Parkinson ’ s dis-ease ( PD) , so as to provide a reference on early diagnosis of PD .Methods The expression levels of miR -133 b in cerebro-spinal fluid of 46 patients with PD , 25 patients with headache and 22 healthy people were detected by Reverse transcription polymerase chain reaction (RT-PCR).The correlations of miR-133b expression and the clinicopathological features of PD were analyzed.Results The expression level of miR -133b in cerebrospinal fluid of patients with PD was significantly higher than headache group and healthy control group (all P〈0.05).The expression level of miR -133b in cerebrospinal fluid had a positive correlation with Unified Parkinson ’s Disease Rating Scale (UPDRS) (r=0.74, P〈0.05).The critical values for miR-133b in cerebrospinal fluid were detected at 0.672 through the ROC curves.Under the critical value, the sensitivity of miR-133b was 87.7%and the specificity was 79.3%.Conclusion The detection of miR -133b in cerebrospinal fluid not only contributes to the diagnosis of PD , but also be as an index to judge the condition of PD .
出处 《现代中西医结合杂志》 CAS 2014年第24期2656-2658,共3页 Modern Journal of Integrated Traditional Chinese and Western Medicine
关键词 帕金森病 脑脊液 miR-133b 生物标志物 Parkinson' s disease cerebrospinal fluid miR- 133b biomarker
  • 相关文献

参考文献13

  • 1帕金森病诊疗指南[J].中国临床医生杂志,2010,38(2):77-79. 被引量:23
  • 2Baraniskin A, Kuhnhenn J, Schlegel U, et al. Identification of mi- croRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma[ J]. Neuro Oncol,2012,14(1) :29 - 33.
  • 3Machina A, Ohkubo T,Yokota T. Circulating microRNAs in the ce- rebrospinal fluid of patients with brain diseases [ J]. Methods Mol Biol,2013,1024:203 - 209.
  • 4Kim J, Inoue K, Ishii J,et al. A MicroRNA feedback circuit in mid- brain dopamine neurons [ J ]. Science, 2007,317 ( 5842 ) : 1220 - 1224.
  • 5Dexter DT,Jenner P. Parkinson disease: from pathology to molecu-lar disease mechanisms[ J]. Free Radic Biol Med,2013,62 : 132 - 144.
  • 6杨丽立,王维治.神经变性疾病脑脊液生物学标志物研究进展[J].中国现代神经疾病杂志,2013,13(2):102-109. 被引量:4
  • 7Ascherio A,Lewitt PA,Xu K,et al. Urate as a predictor of the rate of clinical decline in Parkinson disease[ J]. Arch Neurol,2009,66 (12) :1460 - 1468.
  • 8Lewitt P, Schultz L, Auinger P,et al. CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease[ J]. Brain Res,2011,1408 :88 -97.
  • 9Shi M,Bradner J,Hancock AM,et al. Cerebrospinal fluid biomark- ers for Parkinson disease diagnosis and progression [ J]. Ann Neu- ro1,2011,69(3 ) :570 - 580.
  • 10Patron JP,Fendler A ,Bild M ,et al. MiR - 133b targets antiapoptotic genes and enhances death receptor-induced apoptosis [ J ]. PLoS One,2012,7 (4) :e35345.

二级参考文献54

  • 1Forlenza OV, Diniz BS, Gattaz WF. Diagnosis and biomarkers ofpredementia in Alzheimer's disease. BMC Med, 2010,8:89.
  • 2Rieckmann P, Toyka KV; Austrian - German > Swiss MultipleSclerosis Therapy Consensus Group. Escalating immunotherapy ofmultiple sclerosis. Eur Neurol, 1999, 42:121-127.
  • 3Norgren N, SundstrQm P, Svenningsson A, Rosengren L, StigbrandT, Gunnarsson M. Neurofilament and glial fibrillary acidic proteinin multiple sclerosis. Neurology, 2004, 63:1586-1590.
  • 4Brettschneider J, Petzold A, Junker A,Tumani H. Axonal damagemarkers in the cerebrospinal fluid of patients with clinicallyisolated syndrome improve predicting conversion to definitemultiple sclerosis. Mult Scler, 2006, 12:143-148.
  • 5Tumani H, Hartung HP, Hemmer B, Teunissen C,Deisenhammer F, Giovannoni G, Zettl UK; BioMS Study Group.Cerebrospinal fluid biomarkers in multiple sclerosis. NeurobiolDis, 2009, 35:317-127.
  • 6Teunissen CE, Iacobaeus E, Khademi M, Brundin L, Norgren N,Koel-Simmelink MJ, Schepens M, Bouwman F,Twaalfhoven HA,Blom HJ, Jakobs C, Dijkstra CD. Combination of CSF N -acetylaspartate and neurofilaments in multiple sclerosis. Neurology,2009,72:1322-1329.
  • 7Frederiksen J, Kristensen K, Bahl JM, Christiansen M. Tau protein:a possible prognostic factor in optic neuritis and multiple sclerosis.Mult Scler, 2012,18:592-599.
  • 8Bartosik-Psujek H, Stelmasiak Z. The CSF levels of total-tau andphosphotau in patients with relapsing-remitting multiple sclerosis.J Neural Transm, 2006,113:339-345.
  • 9Fukumoto H, Tokuda T, Kasai T, Ishigami N, Hidaka H, Kondo M,Allsop D, Nakagawa M. High - molecular - weight beta - amyloidoligomers are elevated in cerebrospinal fluid of Alzheimer patients.FASEB J, 2010, 24:2716-2726.
  • 10Maruyama M, Arai H, Sugita M, Tanji H, Higuchi M, Okamura N,Matsui T, Higuchi S, Matsushita S, Yoshida H, Sasaki H.Cerebrospinal fluid amyloid beta (1-42} levels in the mild cognitiveimpairment stage of Alzheimer's disease. Exp Neurol, 2001,172:433-436.

共引文献25

同被引文献35

  • 1Dexter DT, Jenner P. Parkinson disease:from pathology to molecular disease mechanisms[ J]. Free Radic Biol Med, 2013,62(5) :132-144.
  • 2Sui Y, Bullock KM, Erickson MA, et al. Alpha synuclein is transported into and out of the brain by the blood-brain barrier[ J]. Peptides ,2014,62 : 197-202.
  • 3Aldakheel A, Kalia LV, Lang AE. Pathogenesis-targeted, disease-modifying therapies in Parkinson disease [ J ]. Neurotherapeutics ,2014,11:6-23.
  • 4Puchalowicz K, Tarnowski M, Baranowska-Bosiacka I, et al. P2X and P2Y receptors-role in the pathophysiology of the nervous system [ J ]. Int J Mol Sci, 2014, 15 (12) : 23672-23704.
  • 5Chiu C, Yeh T, Lai S, et al. Neuroprotective effects of aldehyde dehydrogenase 2 activation in rotenone-induced cellular and animal models of parkinsonism [ J ]. Exp Neuro1,2015 ,263 :244-253.
  • 6Kouti L, Noroozian M, Akhondzadeh S, et 8.l. Nitric oxide and peroxynitrite serum levels in Parkinson' s disease: correlation of oxidative stress and the severity of the disease[J]. Eur Rev Med Pharmacol Sci, 2013,17 (7) : 964-970.
  • 7Riley BE, Olzmann JA. A polyubiquitin chain reaction: parkin recruitment to damaged mitochondria [ J ]. PLoS Genet,2015,11 ( 1 ) : e1004952.
  • 8Shiba-FukushimaK, Arano T, Matsumoto G, et al. Phosphorylation of mitoehondrial polyubiquitin by PINK1 promotes parkin mitochondrial tethering[J]. PLoS Genet, 2014,10(12) :1-18.
  • 9Mencacci NE, Bras J, Hersheson J, et al. Parkinson' s disease in GTP cyclohydrolase 1 mutation carriers [ J ]. Brain ,2014,137:2480-2492.
  • 10Zhang H, Song N, Jiang H, et al. Brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor inhibit ferrous iron influx via divalent metal transporter 1 and iron regulatory protein 1 regulation in ventral mesencephalic neurons [ J ]. BBA Mol Cell Res, 2014,1843 ( 12 ) : 2967-2975.

引证文献2

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部